Samsung Biologics has officially begun construction of its Plant 4 in Incheon, South Korea.
Dubbed the “Super Plant”, the new, multi-story 238,000-square-meter construction will be the world’s largest biopharmaceutical manufacturing facility of its kind boasting 256,000 litres total manufacturing capacity.
In a joint event with the Korean government and the Incheon City, Samsung Biologics showcased a virtual groundbreaking ceremony in light of COVID-19 protocols and announced an investment plan to build the “Future of Biopharma.”
Upon completion of Plant 4, Samsung Biologics is expected to be accountable for a third of the total global bio-CMO manufacturing capacity, offering a combined sum of 620,000 litres from a single site.
Plant 4 also features a modular design that will allow flexibility for certain parts of the plant to begin manufacturing activities by the end of 2022, with the goal to commence full operations in 2023.
Designed to scale to the varying needs of clients from large-scale commercial manufacturing to sCMO, Plant 4 will be the most flexible one to date with a diverse line-up of bioreactors.
The Super Plant will also provide a full range of CDO, CMO, CRO processes to offer a complete one-stop service including early-stage development capabilities and large-scale commercial manufacturing with a full QC Lab.